Is Recombinant Growth Hormone Therapy Associated With Increased Intraoccular Pressure?
- Conditions
- Growth Hormone TreatmentGlaucoma
- Interventions
- Other: Measuring intraoccular pressure
- Registration Number
- NCT00867971
- Lead Sponsor
- Assaf-Harofeh Medical Center
- Brief Summary
Recombinant growth hormone is a common therapy in the pediatric population. A number of associated side effects have been described. Several years ago, a case report was published concerning a child that was treated with RGH and developed acute glaucoma. To date no study has evaluated the connection.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- UNKNOWN
- Sex
- All
- Target Recruitment
- 100
Inclusion Criteria
- Age 6-18 years
- treatment with recombinant growth hormone
Exclusion Criteria
- Underlying Chronic diseases
- Family history of eye diseases
- elevated occular pressure prior to starting treatment
Study & Design
- Study Type
- OBSERVATIONAL
- Study Design
- Not specified
- Arm && Interventions
Group Intervention Description RGH treated Measuring intraoccular pressure - Starting treatment with RGH Measuring intraoccular pressure -
- Primary Outcome Measures
Name Time Method Intraoccular pressure in children treated with RGH 2 years
- Secondary Outcome Measures
Name Time Method
Trial Locations
- Locations (1)
Assaf harofeh medical center
🇮🇱Zerifin, Israel